Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
about
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesTumor-specific delivery of biologics by a novel T-cell line HOZOT.Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells.Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancersTelomelysin shows potent antitumor activity through apoptotic and non-apoptotic cell death in soft tissue sarcoma cells.Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirusAblation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.Telomerase and the endocrine system.Combining conditionally replicating adenovirus-mediated gene therapy with chemotherapy: a novel antitumor approach.Is telomerase a viable target in cancer?Utilizing adenovirus vectors for gene delivery in cancer.Comparison of prostate-specific promoters and the use of PSP-driven virotherapy for prostate cancer.Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine.Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.Detection of circulating tumor cells in cervical cancer using a conditionally replicative adenovirus targeting telomerase-positive cells.Telomerase-specific oncolytic adenovirus: antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells.
P2860
Q26863779-D1E3EAB6-3F69-47F0-9418-751DC90BA993Q30830225-927CDE85-C9E0-4633-9529-AD7D13BAD119Q33844916-9157D9B4-160B-408E-A1E5-C86D28E14B6DQ34317709-0823EEED-1F2E-4292-A97A-EA6EDA9CE3E1Q34347463-636468FC-BAB2-4875-8737-A7D7B33287E9Q34415371-EAD00E98-4A71-4E44-A365-5F673D4FD0E6Q36642630-9206ED37-5FEA-4572-A193-2C0E8E40B1D9Q37054272-55DAF505-AE2E-4832-9930-30F7D110ECC0Q37859251-9AFFA196-9814-463D-B8C0-9661232FD825Q37867584-E4A327D5-689F-45BE-9A20-60932AD6A22CQ37908470-BC0CCB6E-2194-42B2-AE9C-CA45C0F12696Q38176044-B6B4BDE4-59E4-4809-95D8-EE9AC9F2F348Q39181862-1106A59B-B369-4409-90DE-A487A9BE4FE4Q39613754-99DB1780-D614-4A03-B2A7-2D3380004F5BQ40090311-149C605A-A9BD-491E-AD96-FAE383335ADFQ40162348-CA5C29A0-87B6-4C8D-BB1E-C3372D9DFD47Q40907752-C4797229-3E31-48B7-BB9F-BB1CB6041475Q42202353-51E17D2F-4E53-4BC6-9910-53A03FA15E17Q47576014-EA5FA191-68AB-44F8-AA03-804575DDB5CFQ50943815-D1F159B4-91B8-45BC-AE7D-913B08DEB6B2
P2860
Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Intraperitoneal administration ...... with peritoneal dissemination.
@ast
Intraperitoneal administration ...... with peritoneal dissemination.
@en
type
label
Intraperitoneal administration ...... with peritoneal dissemination.
@ast
Intraperitoneal administration ...... with peritoneal dissemination.
@en
prefLabel
Intraperitoneal administration ...... with peritoneal dissemination.
@ast
Intraperitoneal administration ...... with peritoneal dissemination.
@en
P2093
P2860
P921
P356
P1433
P1476
Intraperitoneal administration ...... with peritoneal dissemination.
@en
P2093
M Hashimoto
M Nakamura
M Takakura
T Fujiwara
Y Mizumoto
P2860
P2888
P356
10.1038/CGT.2009.44
P577
2010-01-01T00:00:00Z
P5875
P6179
1048019684